Galactosaminogalactan and Pel are cationic heteropolysaccharides produced by the opportunistic pathogens Aspergillus fumigatus and Pseudomonas aeruginosa, respectively. These exopolysaccharides both contain 1,4-linked N-acetyl-D-galactosamine and play an important role in biofilm formation by these organisms. Proteins containing glycoside hydrolase domains have recently been identified within the biosynthetic pathway of each exopolysaccharide. Recombinant hydrolase domains from these proteins (Sph3 h from A. fumigatus and PelA h from P. aeruginosa) were found to degrade their respective polysaccharides in vitro. We therefore hypothesized that these glycoside hydrolases could exhibit antibiofilm activity and, further, given the chemical similarity between galactosaminogalactan and Pel, that they might display cross-species activity. Treatment of A. fumigatus with Sph3 h disrupted A. fumigatus biofilms with an EC 50 of 0.4 nM. PelA h treatment also disrupted preformed A. fumigatus biofilms with EC 50 values similar to those obtained for Sph3 h . In contrast, Sph3 h was unable to disrupt P. aeruginosa Pel-based biofilms, despite being able to bind to the exopolysaccharide. Treatment of A. fumigatus hyphae with either Sph3 h or PelA h significantly enhanced the activity of the antifungals posaconazole, amphotericin B, and caspofungin, likely through increasing antifungal penetration of hyphae. Both enzymes were noncytotoxic and protected A549 pulmonary epithelial cells from A. fumigatus-induced cell damage for up to 24 h. Intratracheal administration of Sph3 h was well tolerated and reduced pulmonary fungal burden in a neutropenic mouse model of invasive aspergillosis. These findings suggest that glycoside hydrolases can exhibit activity against diverse microorganisms and may be useful as therapeutic agents by degrading biofilms and attenuating virulence.
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biofilm | Aspergillus | Pseudomonas | therapeutics | exopolysaccharide T he mold Aspergillus fumigatus and the Gram-negative bacterium Pseudomonas aeruginosa are opportunistic pathogens that cause pulmonary infection in immunocompromised patients and individuals who suffer from chronic lung diseases such as cystic fibrosis and bronchiectasis. A. fumigatus is the second most common nosocomial fungal infection (1) , and ∼10% of all nosocomial bacterial infections are caused by P. aeruginosa (2) . Mortality associated with P. aeruginosa infections is high (3) and has increased with the emergence of multi-and even panresistance to antibiotics (3, 4) . Similarly, invasive aspergillosis is associated with mortality rates of up to 50% (5) , and increasing rates of antifungal resistance have been reported worldwide (6) . These factors underscore the urgent need for new effective therapies for these infections.
Although A. fumigatus and P. aeruginosa are members of different taxonomic kingdoms, both produce biofilms that constitute a protective lifestyle for the organism. Biofilms are complex communities of microorganisms that grow embedded in an extracellular matrix composed of DNA, protein, and exopolysaccharide (7) . Biofilm formation provides a significant advantage to these organisms because the matrix mediates adherence to host cells (8, 9) and aids in the resistance to both antimicrobial agents (10, 11) and host-immune defenses (12, 13) . A. fumigatus biofilm formation depends on the cationic polysaccharide galactosaminogalactan (GAG), a heteroglycan composed of α1,4-linked galactose and N-acetyl-D-galactosamine (GalNAc) that is partially deacetylated (14, 15) . In comparison, P. aeruginosa has the genetic capacity to produce three biofilm exopolysaccharides: alginate, Psl and Pel (16) . GAG shares several similarities with Pel, which has been identified as a cationic heteroglycan composed of 1,4-linked GalNAc and N-acetyl-D-glucosamine (GlcNAc) (17) . Like GAG, the cationic nature of Pel results from partial deacetylation of the polymer (17) . Most clinical and environmental isolates of P. aeruginosa use Pel and Psl during biofilm formation (18) . Alginate is dispensable for biofilm formation and is only observed in chronic pulmonary infection when strains switch to a mucoid phenotype (18, 19) .
Strains of Aspergillus and P. aeruginosa with impaired GAG, or Pel and Psl biosynthesis exhibit attenuated virulence (20, 21) , suggesting that targeting these exopolysaccharides may be a
Significance
The production of biofilms is an important strategy used by both bacteria and fungi to colonize surfaces and to enhance resistance to killing by immune cells and antimicrobial agents. We demonstrate that glycoside hydrolases derived from the opportunistic fungus Aspergillus fumigatus and Gram-negative bacterium Pseudomonas aeruginosa can be exploited to disrupt preformed fungal biofilms and reduce virulence. Additionally, these glycoside hydrolases can be used to potentiate antifungal drugs by increasing their hyphal penetration, to protect human cells from fungal-induced injury, and attenuate virulence of A. fumigatus in a mouse model of invasive aspergillosis. The findings of this study identify recombinant microbial glycoside hydrolases as promising therapeutics with the potential for antibiofilm activity against pathogens across different taxonomic kingdoms.
useful therapeutic strategy. We previously demonstrated that recombinant glycoside hydrolases PelA h and PslG h , encoded in the pel and psl operons of P. aeruginosa, respectively, target and selectively hydrolyze the Pel and Psl exopolysaccharide components of the Pseudomonas biofilm matrix (22) . Treatment with these enzymes rapidly disrupts established biofilms, increasing the susceptibility of P. aeruginosa to human neutrophil killing and potentiation of the antibiotic colistin (22) .
Our recent work on Aspergillus has identified a cluster of five genes that encode the proteins necessary for GAG biosynthesis (15) . As with P. aeruginosa, we found that the product of one of these genes contains a glycoside hydrolase domain, Sph3 h , which is capable of hydrolyzing purified and cell wall-associated GAG (23) . In the present study, we assessed the therapeutic potential of Sph3 h in disrupting fungal biofilms. We establish that the exogenous addition of Sph3 h is capable of rapidly disrupting existing biofilms of this organism at nanomolar concentrations. Additionally, we demonstrate cross-kingdom activity, because the P. aeruginosa glycoside hydrolase, PelA h , was able to disrupt A. fumigatus biofilms. Whereas Sph3 h was able to bind Pel, it was unable to disrupt preformed P. aeruginosa Pel-mediated biofilms. Treatment with Sph3 h or PelA h increased the susceptibility of wild-type and azole-resistant A. fumigatus strains to lipophilic antifungal drugs. Kinetic studies with labeled posaconazole indicate that the increased susceptibility to antifungals is due to increased penetration of fungal cells by these agents. Both Sph3 h and PelA h were nontoxic to mammalian cells and protected epithelial cells from A. fumigatus-induced damage for up to 24 h. Intratracheal delivery of Sph3 h was well tolerated by mice and significantly reduced the fungal burden of immunocompromised mice infected with A. fumigatus. Our results suggest that glycoside hydrolases have the potential to be effective antibiofilm therapeutics that can mediate activity against evolutionarily diverse microorganisms.
Results
Sph3 h Disrupts Preformed A. fumigatus Biofilms. Our previous work demonstrated that Sph3 h from A. fumigatus and Aspergillus clavatus can hydrolyze both purified and cell wall-bound GAG on young hyphae (23) . We therefore sought to determine whether the degradation of GAG by Sph3 h could disrupt established A. fumigatus biofilms. Treatment with Sph3 h for 1 h disrupted established A. fumigatus biofilms with an effective concentration for 50% activity (EC 50 ) of 0.45 ± 1.31 nM (Fig.  1A) . Biofilm disruption was associated with a marked reduction in hyphae-associated GAG as detected by lectin staining (Fig. 1 B and C) and scanning electron microscopy ( Fig. 1D) . A catalytic variant Sph3 h D166A, which does not mediate GAG hydrolysis (23) , displayed a greater than 500-fold reduction in antibiofilm activity (Fig. 1A ) and failed to mediate degradation of biofilmassociated GAG ( Fig. 1 B and C) . Collectively, these data suggest that biofilm disruption is mediated through the enzymatic hydrolysis of GAG.
To validate that fungal biofilm disruption by Sph3 h is not restricted to the A. fumigatus laboratory strain Af293, the activity of Sph3 h was evaluated against four clinical A. fumigatus isolates. Sph3 h disrupted biofilms of all isolates tested at EC 50 values <0.15 nM (Fig. S1 ). These results confirm the role of GAG in biofilm formation and indicate that Sph3 h exhibits antibiofilm activity across a wide range of A. fumigatus strains.
The Bacterial Hydrolase PelA h Hydrolyses GAG and Disrupts Fungal Biofilms. Given that GAG and Pel are both cationic exopolysaccharides containing 1,4-linked GalNAc (14, 17), we hypothesized that PelA h might exhibit activity against GAG. Consistent with this hypothesis, an in vitro reducing sugar assay demonstrated that PelA h was capable of hydrolyzing purified GAG (Fig. S2) . Furthermore, using the crystal violet biofilm assay, we found that PelA h disrupted A. fumigatus fungal biofilms with an EC 50 value of 2.80 ± 1.14 nM (Fig. 2A) . The treatment of A. fumigatus hyphae with PelA h also resulted in a reduction in the amount of cell wall-associated GAG ( Fig. 2 B-D) as was observed with Sph3 h treatment. The PelA h catalytic variant, PelA h E218A, which is markedly impaired in Pel hydrolysis and is inactive against P. aeruginosa biofilms (22), did not significantly hydrolyze GAG at concentrations as high as 12 μM (Fig.  S2 ). Consistent with this observation, PelA h E218A was also several hundred-fold less active against A. fumigatus biofilms and did not degrade hyphae-associated GAG ( Fig. 2 B and C) . These results suggest that PelA h disrupts A. fumigatus biofilms through the hydrolysis of biofilm-associated GAG.
Sph3 h Binds Pel but Does Not Disrupt Established P. aeruginosa
Biofilms. Given that PelA h can hydrolyze GAG and disrupt GAG-mediated biofilms, we hypothesized that Sph3 h may exhibit activity against Pel and Pel-mediated biofilms. The inability to purify sufficient quantities of Pel precluded us from using it as a substrate. Therefore, to examine whether Sph3 h was capable of hydrolyzing Pel, the enzyme was exogenously applied to biofilms produced by the Pel overproducing P. aeruginosa strain PAO1 ΔwspF Δpsl P BAD pel. Treatment of these established biofilms with Sph3 h did not affect levels of Pel within the biofilms as visualized by lectin staining (Fig. 3 A and B) , nor did it reduce biofilm biomass, even at concentrations exceeding 10 μM (Fig. 3C) .
Because Sph3 h did not hydrolyze Pel within P. aeruginosa biofilms, we tested whether the enzyme was capable of recognizing and binding this polysaccharide. Using an ELISA-based binding assay, we observed dose-dependent binding of Sph3 h to culture supernatants from the Pel overproducing P. aeruginosa strain, but not from supernatants of the Pel-deficient strain PAO1 ΔwspF Δpel Δpsl (Fig. 3D ). These data suggest that the inability of Sph3 h to disrupt Pel-mediated biofilms is likely a consequence of an inability to hydrolyze Pel rather than being unable to bind the polysaccharide. Dose-dependent binding of the inactive Sph3 h D166A variant to GAG-containing culture supernatants was also observed (Fig. S3) , suggesting that binding of hydrolases to exopolysaccharides is insufficient to disrupt established biofilms in the absence of enzymatic cleavage of the polymer.
Sph3 h and PelA h Potentiate Antifungals by Enhancing Their Intracellular
Penetration. The Pel polysaccharide enhances resistance to several antibiotics including aminoglycosides and colistin (22, 24, 25) . Because biofilm formation by A. fumigatus is associated with increased resistance to a number of antifungal agents (26) (27) (28) , we hypothesized that GAG may have an analogous function to Pel in enhancing resistance to antifungal agents. To test this hypothesis, we investigated whether Sph3 h or PelA h could potentiate the activity of commonly used antifungal drugs. Treatment of established fungal biofilms with either enzyme resulted in a significant reduction in the MIC 50 of the azole posaconazole, the polyene amphotericin B, and the echinocandin caspofungin (Fig. 4A) . Sph3 h or PelA h treatment produced a similar increase in sensitivity to posaconazole for both azole-sensitive and azole-resistant strains of A. fumigatus (Fig.   S4 ). Susceptibility to voriconazole, a smaller and more polar azole, was unaffected by treatment with either glycoside hydrolase (Fig. 4A ). Because both posaconazole and voriconazole have the same intracellular target, these findings suggest that cationic GAG mediates antifungal resistance by hindering cellular uptake of large, nonpolar molecules such as posaconazole. To investigate this hypothesis, the effect of Sph3 h on intracellular penetration of posaconazole was examined by using posaconazole conjugated to the fluorophore BODIPY (BDP-PCZ). Previous work has established that BDP-PCZ displays similar cellular and subcellular pharmacokinetics to unmodified posaconazole (29) . Fluorometric studies revealed that Sph3 h treatment resulted in higher accumulation of BDP-PCZ within A. fumigatus hyphae (Fig. 4B) . This finding indicates that GAG protects A. fumigatus from the action of lipophilic antifungals by limiting their penetration into hyphae.
Recombinant Sph3 h and PelA h Protect Epithelial Cells from Damage by A. fumigatus. A. fumigatus GAG-mediated adherence is required for A. fumigatus to damage A549 pulmonary epithelial cells in vitro (20) . We therefore tested whether treatment with either Sph3 h or PelA h could protect epithelial cells from fungalinduced injury by using an established chromium ( 51 Cr) release damage assay (30) . We first established that the enzymes were not cytotoxic and that the addition of Sph3 h or PelA h to uninfected A549 cell monolayers did not cause detectable cellular damage (Fig. S5A) lung fibroblast cell line (Fig. S5B ). These data are consistent with the lack of cytotoxicity previously reported for PelA h (22) . Next, we assessed whether Sph3 h or PelA h were able to protect A549 cell monolayers from damage by A. fumigatus. Sph3 h significantly reduced epithelial cell injury for up to 24 h (Fig. 5A ). Treatment with PelA h also protected epithelial cells from A. fumigatus-induced damage (Fig. 5A) . The protective effect of PelA h was shorter than that observed with Sph3 h , and was lost before 24 h of treatment. The addition of protease inhibitors extended PelA h -mediated epithelial cell protection to 24 h (Fig.  S5C) , suggesting that the decrease in PelA h -mediated protection was likely due to proteolytic degradation of the recombinant protein. Epithelial cell protection was not observed with the catalytic variants, PelA h E218A or Sph3 h D166A, suggesting that the hydrolytic activity of the enzymes is required for protection (Fig. 5A) .
Intratracheal Sph3 h Is Well Tolerated, and Attenuates Fungal Virulence in an Immunocompromised Mouse Model of Pulmonary
Aspergillosis. Given the ability of Sph3 h to protect epithelial cells for more than 24 h, this hydrolase was selected for evaluation in vivo. BALB/c mice treated intratracheally with doses up to 500 μg of Sph3 h exhibited no signs of stress, weight loss, or change in body temperature after treatment ( Fig. S6 A and B) . Additionally, no significant increase in pulmonary injury or inflammation between treated and untreated mice were observed as measured by bronchoalveolar lavage lactate dehydrogenase activity and total pulmonary leukocyte populations ( Fig. 5B and Fig. S6C ). Collectively these results suggest that a single intratracheal dose of Sph3 h is well tolerated by mice.
To determine the ability of Sph3 h to attenuate virulence of A. fumigatus, neutropenic BALB/c mice were infected intratracheally with A. fumigatus conidia with or without the coadministration of 500 μg of Sph3 h . Four days after infection, mice infected with A. fumigatus and treated with Sph3 h had a significantly lower pulmonary fungal burden to untreated, infected mice as measured by both fungal DNA (Fig. 5C ) and pulmonary galactomannan content (Fig. S7) . The fungal burden of the Sph3 h -treated mice was similar to that observed with mice infected with the GAG-deficient hypovirulent strain Δuge3 (20) . Consistent with the fungal burden data, histopathologic examination of lung sections revealed the presence of fungal lesions in untreated, infected mice, but no detectable lesions in the lungs of infected mice treated with Sph3 h , or those infected with conidia of the Δuge3 mutant (Fig. 5D ). These findings suggest that Sph3 h -mediated degradation of GAG can limit the growth of A. fumigatus in vivo, to the same degree as is observed with GAG-deficient organisms.
Discussion
In this study, we demonstrate that the fungal glycoside hydrolase Sph3 h is able to degrade preformed A. fumigatus biofilms. This study is an example of the use of a glycoside hydrolase to disrupt a fungal biofilm. Further, we establish that the glycoside hydrolase PelA h displays activity against biofilms formed by organisms across different microbial kingdoms. Both glycoside hydrolases potentiated the penetration and activity of antifungal agents in vitro, exhibited no toxicity against mammalian cells, and protected epithelial cells from A. fumigatus-induced damage. Pulmonary administration of Sph3 h was well tolerated and limited fungal growth in an immunocompromised mouse model, suggesting that these enzymes are promising therapeutic agents for the treatment of fungal disease.
The mechanism by which the biofilm matrix enhances A. fumigatus resistance to antifungals is poorly understood. The effect of hydrolase treatment on the antifungal sensitivity of A. fumigatus provides some insight into this question and establishes a role for GAG in biofilm-associated antifungal resistance. Multiple observations suggest that GAG enhances antifungal resistance by acting as a barrier to antifungal penetration of hyphae. First, glycoside hydrolase degradation of GAG enhanced the activity of multiple antifungals with different mechanisms of action. Second, the activity of posaconazole, but not voriconazole, was enhanced although both azoles target the same enzyme, CYP51A. These hydrolases also display similar activity against azole-resistant and azole-sensitive strains. The cationic nature of GAG may explain the differential effects on voriconazole compared with other antifungals. The GAG barrier would be predicted to be most effective against large, lipophilic or cationic antimicrobial agents, and thus therapeutic hydrolases may be most effective as adjuvants for lipophilic antifungals. Previous studies have reported that the enzymatic degradation of neutral α-glucans of A. fumigatus did not enhance susceptibility to antifungals (31) , further supporting our hypothesis that exopolysaccharide charge plays a role in mediating antibiotic resistance. Similarly, hydrolysis of cationic Pel exopolysaccharide by PelA h enhances the activity of the polycationic antibacterial colistin (22) . Interestingly, degradation of biofilm-associated extracellular DNA (eDNA) has been reported to enhance A. fumigatus susceptibility to caspofungin and amphotericin B, although the effects on posaconazole and voriconazole susceptibility were not reported in the study (26) . Recent work has suggested that Pel anchors eDNA within P. aeruginosa biofilms through charge-charge interactions (17) . Given the similarities between Pel and GAG, it is possible that GAG-mediated binding of eDNA may also contribute to enhancing antifungal resistance.
The results of these studies add to an emerging body of evidence that fungal biofilms share structural (32) (33) (34) (35) and functional (26, 36, 37) similarity with those formed by pathogenic bacteria. The finding that glycoside hydrolases can display activity against the exopolysaccharides and biofilms of both fungi and bacteria provides evidence that these similarities could potentially be exploited for the development of therapeutics active against both organisms. Additionally, the similarity between the exopolysaccharides of P. aeruginosa and A. fumigatus, coupled with the interspecies activity of their glycoside hydrolases, suggest the intriguing possibility that exopolysaccharide interactions may occur between organisms during multispecies biofilm formation. Cocolonization with P. aeruginosa and A. fumigatus is not uncommon in patients with chronic pulmonary disease such as cystic fibrosis (38) . Although studies of the formation of mixed fungal-bacterial biofilms during pulmonary infection are limited, a recent study of patients with chronic lung disease reported that antibacterial therapy for P. aeruginosa was associated with a reduction in fungal colonization, suggesting the possibility of microbial cooperation (39) . Further studies examining the role of cross-species exopolysaccharide and exopolysaccharide-modifying enzyme interactions are required to establish a role for cooperative biofilm interactions in pulmonary disease.
Whereas PelA h exhibited cross-species activity and disrupted preformed fungal biofilms, Sph3 h bound Pel, but was unable to disrupt established Pel-mediated biofilms. This difference in activity may reflect differences in the composition or conformation of each polysaccharide because GAG is a heteropolymer of GalNAc and galactose whereas Pel is comprised of GalNAc and GlcNAc. It is likely that these differences influence the ability of Sph3 h and PelA h to hydrolyze the polymer. The inability of Sph3 h to degrade preformed P. aeruginosa biofilms may suggest that mature Pel adopts a configuration or undergoes postsynthetic modification that renders it incompatible with the catalytic active site of Sph3 h and resistant to cleavage. Detailed studies of these enzymes to determine the mechanisms underlying their differential activity against Pel will require purified polysaccharide, which is not available.
Both Sph3 h and PelA h were found to be noncytotoxic, and a single dose of intratracheal Sph3 h was well tolerated by BALB/c mice. Coadministration of Sph3 h with wild-type conidia to neutropenic mice greatly reduced fungal outgrowth within the lungs of these mice. Together these results provide proof-of-concept that the glycoside hydrolases can be used to improve the outcome of fungal infection, with minimal side effects and toxicity. These findings will pave the way for future work to evaluate the utility of these agents as antifungal therapeutics including detailed pharmacokinetic and toxicity studies, and the evaluation of these enzymes for the treatment of established fungal infections alone and in combination therapy with lipophilic antifungal agents such as posaconazole or amphotericin B.
Methods
Strains and Culture Conditions. Strains used in this study are detailed in Table  S1 , and detailed culture conditions are described in SI Methods.
Recombinant Hydrolase Expression and Purification. Hydrolases were expressed and purified as described (22, 23) .
Treatment of A. fumigatus with Glycoside Hydrolases. To visualize the effects of hydrolases on cell wall-associated GAG, hyphae were treated with recombinant hydrolases and stained with fluorescein-conjugated soybean agglutinin as described (23), with minor modifications. Hyphae were counterstained with a 1:1,000 dilution of DRAQ5 (eBioscience) in PBS for 5 min before paraformaldehyde (PFA) fixation. Complete image acquisition and processing methods can be found in SI Methods. To study the effects of hydrolases on biofilms, 10 4 conidia were grown in Brian media in polystyrene, 96-well plates for 19 h at 37°C and 5% CO 2 and then treated with the indicated concentration of glycoside hydrolase in PBS for 1 h at room temperature. Biofilms were then gently washed, stained with 0.1% (wt/vol) crystal violet and destained with 100% ethanol for 10 min. The optical density of the destain fluid was measured at 600 nm (OD 600 ).
Scanning Electron Microscopy. Complete sample preparation and processing methods are detailed in SI Methods.
Treatment of P. aeruginosa with Glycoside Hydrolases. For biofilm disruption, static P. aeruginosa cultures were grown for 22 h at 30°C, at which point the planktonic cells were aspirated, and LB + 0.5% arabinose + 0.5 μM glycoside hydrolase was added for an additional 3 h. For the detection of Pel, samples were incubated with 30 μg/mL fluorescein-conjugated Wisteria fluoribunda lectin for 2 h at 4°C, fixed with 8% (wt/vol) PFA for 20 min at 4°C and imaged as detailed in SI Methods. The ability of hydrolases to disrupt established biofilms were studied as described (22) .
Quantification of Hydrolase Binding to Culture Supernatants. Details of culture supernatant production and hydrolase binding quantification can be found in SI Methods.
Effects of Glycoside Hydrolases on Antifungal Susceptibility of A. fumigatus. Fungal biofilms were prepared in tissue culture treated with 24-well plates in RPMI medium 1640 (Life Technology) buffered with Mops [3-(N-Morpholino) Propane-Sulfonic Acid] (RPMI-Mops) (Fisher) for 9 h at 37°C, 5% CO 2 . Serial dilutions of antifungal compounds with or without 0.5 μM Sph3 h or PelA h were added to wells, and the plates were incubated at 37°C and 5% CO 2 for 15 h. Fungal viability was measured by using the sodium 3′-{1-[(phenylamino)-carbony]-3,4-tetrazolium}-bis(4-methoxy-6-nitro)benzene-sulfonic acid hydrate (XTT) metabolic assay as described (40) . The concentration of antifungal resulting in a 50% decrease in viability (MIC 50 ) was used as a measure of antifungal effect. in each well of a 96-well black, clear-bottom plate for 8 h at 37°C, 5% CO 2 . Hyphae were treated with 1 μM Sph3 h in PBS for 90 min at 37°C, 5% CO 2 then exposed to 2 μg/mL BDP-PCZ for 10 min. The plate was then read by using an Infinite M1000 fluorescent plate reader with excitation wavelengths of 532 and 488 nm for RFP and BDP-PCZ, respectively. Background fluorescence was subtracted from both RFP and BDP-PCZ signals, and the BDP-PCZ signal was then normalized to total RFP fluorescence for each well.
Effects of Glycoside Hydrolases on A. fumigatus-Induced Epithelial Cell Damage. A549 pulmonary epithelial cell damage by A. fumigatus was tested by using the 51 Cr release assay as described (20, 30) . Recombinant hydrolases were added to the A549 cultures at the time of infection at a final concentration of 0.5 μM.
Characterization of Pulmonary Damage by Sph3 h . All procedures involving mice were approved by the Animal Care Committees of the McGill University Health Centre. Female BALB/c mice 5-6 wk of age were anesthetized with isoflurane and administered a single endotracheal injection of 500 μg of Sph3 h in 50 μL PBS and monitored daily for 7 d. Mice were then euthanized by CO 2 overdose, and their airways lavaged with 1 mL of PBS that was administered and collected through a needle inserted in the trachea. A total of two lavages were performed and pooled. The presence of LDH in the BAL fluid was used as an indicator of pulmonary damage; LDH activity was measured in the fluid by using a commercial assay (Promega), as per manufacturer's instructions.
Effects of Sph3 h in a Severely Immunocompromised Mouse Model of Invasive Pulmonary Aspergillosis. Mice were immunosuppressed with cortisone acetate and cyclophosphamide as described (20, 41) . Mice were infected with an endotracheal injection of 5 × 10 3 A. fumigatus conidia, resuspended in either PBS alone, or in combination with 500 μg of Sph3 h . Mice were monitored daily, and moribund animal were euthanized. At 4 d after infection, mice were euthanized and their lungs were harvested. For fungal burden analysis, lungs were homogenized in 5 mL of PBS containing protease inhibitor mixture (Roche), and aliquots were stored at −80°C until use. Pulmonary fungal burden was determined as described (15) , and as detailed in SI Methods.
